News for Your Practice

Risk of autism is significantly increased with prenatal exposure to valproate

Prenatal exposure to valproate significantly raises the risk of autism spectrum disorder and childhood autism. Risks must be balanced against treatment benefits for mothers with epilepsy.




Pregnancy and epilepsy—managing both, in one patient
Nitin K. Sethi, MD; Amy Wasterlain; Cynthia L. Harden, MD (June 2011)

Guidelines confirm safety of pregnancy in women who have epilepsy—with caveats
Janelle Yates, Senior Editor (September 2009)

Prenatal exposure to valproate correlates with an increased risk of autism spectrum disorder and childhood autism in offspring, according to a study published in the Journal of the American Medical Association (JAMA).

Jakob Christensen, PhD, from Aarhus University Hospital in Denmark, and colleagues examined whether prenatal exposure to valproate correlates with the risk of autism in offspring in a population-base study involving 655,615 children born from 1996 through 2006 in Denmark.

Of the cohort, 5,437 were identified with autism spectrum disorder, including 2,067 with childhood autism. After 14 years of follow-up, the researchers found that the estimated absolute risk of autism spectrum disorder was 1.53%, and that of childhood autism was 0.48%. The absolute risks for the 508 children exposed to valproate were 4.42% for autism spectrum disorder (adjusted hazard ratio [aHR], 2.9) and 2.50% for childhood autism (aHR, 5.2). On restriction of the cohort to the 6,584 children born to women with epilepsy, the absolute risk of autism spectrum disorder was 2.44% for those not exposed to valproate (6,152 children) versus 4.15% for those exposed to valproate (432 children; aHR, 1.7); for childhood autism, the corresponding risks were 1.02% and 2.95% (aHR, 2.9).

“Maternal use of valproate during pregnancy was associated with a significantly increased risk of autism in the offspring, even after adjusting for parental psychiatric disease and epilepsy,” the authors write. “For women of childbearing potential who use antiepileptic medications, these findings must be balanced against the treatment benefits for women who require valproate for epilepsy control.”

One author disclosed financial ties to the pharmaceutical industry.

To read the JAMA abstract, click here.

Copyright © 2013 HealthDay. All rights reserved.

Recommended Reading

Recommendations for gestational diabetes mellitus screening remain unchanged
MDedge ObGyn
Previous abortion no longer a risk factor for preterm birth
MDedge ObGyn
Trial of labor after C-section uncommon, but often successful
MDedge ObGyn
Cervical pessaries improve outcomes in some multiple pregnancies
MDedge ObGyn
Shorter time to delivery seen with misoprostol vs. dinoprostone vaginal insert
MDedge ObGyn
High-risk HPV infection more than doubles odds of preeclampsia
MDedge ObGyn
Laborist model improves obstetric outcomes and is cost-effective
MDedge ObGyn
Placental abruption a strong risk factor for long-term CVD death
MDedge ObGyn
SSRIs in pregnancy
MDedge ObGyn
ACOG: Balance risks when considering early deliveries
MDedge ObGyn